Ind-Swift Laboratories has received approval to incorporate wholly owned subsidiary (WOS) in Dubai, United Arab Emirates (UAE) in the name and style of ‘Ind-Swift (Dubai)’ or such other name as may be approved by the concerned authorities of the UAE.
The WOS intends to strategically invest in pharmaceutical and allied activities. This includes exploring potential acquisitions, tie-ups, or joint ventures. Additionally, the Company aims to establish and operate pharmaceutical manufacturing units. The investment in the wholly owned subsidiary would be a Related Party Transaction. The investment shall be made on arms’ Length basis.
Ind-Swift Laboratories is global manufacturer of Active Pharmaceutical Ingredients (API), Intermediates and formulations (through group collaboration).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: